Fetal exposure to capecitabine and temozolomide during the first trimester: A case report

Maria I Castellanos; Krista J Childress; Mildred Ramirez; Rajkumar Venkatramani

doi:10.1016/j.jogoh.2020.101881

Fetal exposure to capecitabine and temozolomide during the first trimester: A case report

J Gynecol Obstet Hum Reprod. 2020 Jul 23:101881. doi: 10.1016/j.jogoh.2020.101881. Online ahead of print.

Authors

Maria I Castellanos¹, Krista J Childress², Mildred Ramirez³, Rajkumar Venkatramani⁴

Affiliations

¹ Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, United States. Electronic address: mc34@bcm.edu.
² Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, 30322, United States. Electronic address: krista.childress@emory.edu.
³ Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, 77030, United States. Electronic address: mmramire@bcm.edu.
⁴ Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, United States. Electronic address: rajkumar.venkatramani@bcm.edu.

PMID: 32712180
DOI: 10.1016/j.jogoh.2020.101881

Abstract

Literature on the outcome of pregnancy after exposure to capecitabine and temozolomide during the first trimester is scarce. Chemotherapy administration in the first trimester is generally not recommended due the potential risks to the fetus including fetal death and major congenital malformations. Capecitabine and temozolomide are oral chemotherapy agents and pregnancy category D medications, thus the use of these agents in pregnancy is not recommended. We present the case of a 17-year-old female who while receiving cancer treatment, had unintentional exposure to capecitabine and temozolomide during the first trimester of pregnancy, and subsequently delivered a healthy infant.

Keywords: Cancer; Capecitabine; Chemotherapy; Fetus; Pregnancy; Temozolomide.

Publication types

Case Reports